Lion Point Capital LP Raises Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC)

Lion Point Capital LP boosted its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 59.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,000 shares of the biotechnology company’s stock after acquiring an additional 23,000 shares during the period. Benitec Biopharma makes up approximately 4.1% of Lion Point Capital LP’s holdings, making the stock its 10th largest holding. Lion Point Capital LP owned approximately 0.27% of Benitec Biopharma worth $783,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its stake in Benitec Biopharma by 198.5% during the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company’s stock valued at $33,268,000 after acquiring an additional 1,739,904 shares during the period. Ameriprise Financial Inc. increased its stake in Benitec Biopharma by 138.4% during the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock valued at $448,000 after acquiring an additional 20,597 shares during the period. 683 Capital Management LLC bought a new position in Benitec Biopharma during the fourth quarter valued at about $452,000. Northern Trust Corp boosted its holdings in Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 13,425 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company’s stock valued at $24,913,000 after purchasing an additional 1,131,129 shares in the last quarter. 52.19% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BNTC. HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Benitec Biopharma in a report on Monday, March 24th. JMP Securities boosted their target price on Benitec Biopharma from $18.00 to $20.00 and gave the stock a “market outperform” rating in a report on Thursday, April 10th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $24.71.

Insider Activity

In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 900,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the purchase, the director now owns 8,793,245 shares of the company’s stock, valued at $114,312,185. This represents a 11.40% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Benitec Biopharma Stock Up 0.1%

BNTC stock opened at $13.75 on Monday. The business’s fifty day moving average is $13.61 and its 200-day moving average is $11.94. The company has a market cap of $322.45 million, a P/E ratio of -9.11 and a beta of 0.34. Benitec Biopharma Inc. has a twelve month low of $5.74 and a twelve month high of $16.90.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19. Research analysts anticipate that Benitec Biopharma Inc. will post -1.48 earnings per share for the current fiscal year.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.